Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Neurotrope, Inc. (OTC: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, issued a statement on Eli Lilly's (NYSE: LLY) experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease.
Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer stated' "I deeply regret the news released today that Lilly's latest trial of its leading Alzheimer's drug candidate has failed. Lilly's dedication and persistence to finding a cure for this devastating affliction deserves everyone's admiration and gratitude.
Repeated attempts to treat or even slow the relentless progression of Alzheimer's disease by targeting the red flag in patient's brains called amyloid plaques have continued to lead to such disappointing outcomes.
Neurotrope has focused all of its resources on regenerative medicine that would replace the lost synaptic networks that are so consistently associated with the breakdown of human cognitive functions. Bryostatin, a drug that induces growth of new networks to replace those that have degenerated while also degrading plaques and tau tangles, may also address the red flags of this scourge threatening increasing numbers of the world's aging populations. At Neurotrope, we believe that treating Alzheimer's disease is a daunting challenge that will need to be treated by a drug with multi modal efficacy. We believe that our drug bryotstatin may be the drug. The top line results of our Phase 2 study with 148 patients is expected to be announced in April 2017.
We hope, at that time, that a new therapy will be viewed as a possible future treatment for this disease."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Digital Ally (DGLY) Refutes TASER's Attack on ‘292 Patent; Says Nothing New Here
- Celgene (CELG) to Acquire Acetylon Pharmaceuticals
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Related EntitiesCarl Icahn
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!